Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202. ASH Annual Meeting and Exposition 2018, abstract 6.
Oratie Erik Klok: Kijken naar de persoon om het bloedstolsel heen
mrt 2023 | Benigne hematologie, Vasculaire geneeskunde